Merck & Co., Inc. (BVL:MRKUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 1.26T +73.7% |
| Revenue (ttm) | 231.12B +4.9% |
| Net Income | 8.41B -87.1% |
| EPS | 3.39 -86.9% |
| Shares Out | n/a |
| PE Ratio | 151.20 |
| Forward PE | 17.50 |
| Dividend | 11.88 (2.32%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 149.50 |
| Day's Range | n/a |
| 52-Week Range | 85.25 - 150.66 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck reports Phase 2b MK-6024-013 trial met primary efficacy endpoint
Merck (MRK) announced the presentation of “positive” results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutid...
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company's Phase 2b clinical trial ...
Adagene completes enrollment in muzastotug trial
Adagene (ADAG) announced completion of enrollment in its randomized Phase 2 dose-optimization trial of muzastotug, a masked, anti-CTLA-4 SAFEbody, in combination with Merck’s (MRK) anti-PD-1 therapy, ...
Healthcare Stocks Fall as Market Rout Spreads
Global healthcare stocks fell Friday, hit by a rout that reached Europe and Asia and spread across sectors after hammering AI trades and U.S. markets earlier in the week.
Merck gets US FDA emergency use nod for treatment of screwworm in dogs
The US Food and Drug Administration on Tuesday issued an emergency use authorization for Merck's Bravecto tablets to treat New World screwworm in dogs and puppies, expanding treatment options to com...
Merck initiates Phase 3 study of Ohtuvayre
Merck (MRK) announced the initiation of ENHANCE-3, a Phase 3 randomized clinical trial evaluating Ohtuvayre (ensifentrine) for the prevention of chronic obstructive pulmonary disease exacerbations in ...
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized ...
Merck downgraded to Hold from Buy at DZ Bank
DZ Bank analyst Elmar Kraus downgraded Merck (MRK) to Hold from Buy with a $153 price target
Merck price target raised to $140 from $125 at Freedom Broker
Freedom Broker raised the firm’s price target on Merck (MRK) to $140 from $125 and keeps a Hold rating on the shares. The firm raised its valuation multiple with investors…
Merck price target raised to $155 from $145 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Merck (MRK) to $155 from $145 and keeps a Neutral rating on the shares. Merck delivered a solid ESMO showing and better-than-expected…
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.
Moderna, Merck eye FDA approval for promising cancer vaccine
Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.'
Merck price target lowered to $174 from $177 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Merck (MRK) to $174 from $177 and keeps an Overweight rating on the shares.
Merck price target raised to $175 from $165 at JPMorgan
JPMorgan raised the firm’s price target on Merck (MRK) to $175 from $165 and keeps an Overweight rating on the shares.
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today re...
Merck price target raised to $171 from $170 at Guggenheim
Guggenheim raised the firm’s price target on Merck (MRK) to $171 from $170 and keeps a Buy rating on the shares after updating the firm’s model following the company’s Q3…
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Merck & Co., Inc. ("Merck" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is inve...
Merck & Co. Earnings Call Transcript: Q3 2026
Q3 revenue rose 5% to $18.1B, with new products and oncology and animal health strength. 2026 guidance midpoint increased; 2027 is expected to bring moderate growth amid >$2B of generic and LOE headwinds and continued investment.
Merck & Co. Earnings release: Q3 2026
Merck & Co. released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Merck & Co. Prepared remarks: Q3 2026
Merck & Co. filed a regulatory document on October 29, 2026 disclosing important business information.
Merck & Co. Slides: Q3 2026
Merck & Co. has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Merck & Co. Quarterly report: Q3 2026
Merck & Co. has published its Q3 2026 quarterly earnings report on October 29, 2026.
Merck Stock (MRK) Rises 2% on $830 Million Keytruda Sales Beat, Q3 Forecasts, and Higher Full-Year Profit Outlook
Merck & Co ($MRK) shares rose 2.14% in Thursday premarket trading after the drugmaker beat third-quarter Wall Street estimates and raised its full-year adjusted profit forecast. Strong demand for its…
Merck Revenue Up on Keytruda, Winrevair Growth
Third-quarter profit came in at $5.07 billion, or $2.04 a share, compared with $5.79 billion, or $2.32 a share, a year earlier.
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck topped third-quarter estimates and hiked its adjusted profit outlook. The company's immunotherapy Keytruda, including a newer injectable form of the drug called Qlex, posted stronger-than-expect...